AIxCrypto Holdings, Inc. is a clinical-stage biopharmaceutical company committed to discovering and developing innovative treatments for both adult and pediatric oncology. Its leading investigational therapeutic, QN-302, is a small molecule G-quadruplexes (G4)-selective transcription inhibitor currently progressing through Phase I clinical trials for pancreatic cancer and a range of other solid tumors. The firm is also advancing Pan-RAS, a preclinical-stage program targeting advanced solid tumors. Founded in 1996 and headquartered in Carlsbad, California, the company rebranded from Qualigen Therapeutics, Inc. to AIxCrypto Holdings, Inc. in November 2025.
Faraday Future Supports AIxC’s Full Strategic Pivot to Physical AI and Robot-Sharing and Rental Operations; RoboShare Completes Its First Paid Commercial Order, With an Initial Fleet of More Than 80 Robots in Place
AIxC's RoboShare platform completed its first paid commercial order on August 15, marking the company's transition from digital asset treasury to commercial Physical AI and robot-sharing operations with an initial fleet of over 80 robots.
As majority and controlling shareholder, Faraday Future (FFAI) is supporting AIxC's strategic pivot by providing product, technology, and capital-market support to establish a synergistic ecosystem.
The first commercial deployment involves six robots for an event in Malibu, launching the "Ten-City Strategy" in Los Angeles in partnership with content creator DU$TY.